Three drug trends impacting specialty pharmacy

Posted on April 26, 2016 by henrykotula • Posted in Uncategorized • Tagged ACA, Biosimilars, Breakthrough Therapies, Cancer, Chronic Conditions, Drug Costs, FDA, Health Policy, Hepatitis C, HIV, Multiple Sclerosis, Orphan Drugs, Pharmaceutical, Rheumatoid Arthritis, Specialty Drugs • Leave a comment

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/three-drug-trends-impacting-specialty-pharmacy?cfcache=true

Prescription drug spending surges amid market forces

Posted on March 29, 2016 by henrykotula • Posted in Uncategorized • Tagged ACA, Cancer Drugs, Chronic Hepatitis C, Compounded Medications, FDA, Generic Drugs, Hepatitis C Drugs, Medicaid Expansion, Non-Orphan Drugs, Orphan Drug Act, Orphan Drugs, PCSK9-inhibitors, Prescription Drug Spending, Specialty Medications, Ultra-Orphan Drugs • Leave a comment

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/prescription-drug-spending-surges-amid-market-forces?cfcache=true

Kickbacks, Bribes, and the Horrifying Truth Behind California’s Largest Medical Fraud Scandal

Posted on March 23, 2016 by henrykotula • Posted in Uncategorized • Tagged Adult Entertainers, Bonus Medical Implants, Bribes, Creative Accounting, DOJ, FDA, Federal Employees Compensation Act, Fraud and Abuse, Health Policy, Health System, Hospital, Kickbacks, Mail Fraud, Medi-Cal, Money Laundering, National Healthcare Antifraud Association, Pass-Through Allowance, Political Lobbying, RICO Act, Spinal Fusion Operations, State Compensation Insurance Fund, Tool Fabrication, Unbundled Billing, Unnecessary Surgery, Whistleblower Lawsuit, Workers Comp • Leave a comment

http://www.lamag.com/longform/kickbacks-bribes-and-the-horrifying-truth-behind-californias-largest-medical-fraud-scandal/

Long Beach hospital owner Michael Drobot spent decades bilking the state of millions for unnecessary surgeries with allegedly bogus hardware, and plenty of doctors went along with him – See more at: http://www.lamag.com/longform/kickbacks-bribes-and-the-horrifying-truth-behind-californias-largest-medical-fraud-scandal/#sthash.flf2d3Ck.dpuf

Experts assess Trump’s 7-point healthcare plan

Posted on March 23, 2016 by henrykotula • Posted in Uncategorized • Tagged ACA, ACA Repeal, Antitrust, Block Grant Medicaid, FDA, Health Policy, Health Premium Tax Deductions, HSA, Individual Mandate, Interstate Health Insurance, Means-Tested Financial Support, Network Adequacy, Overseas Drug Providers, Price Transparency, Refundable Tax Credit • Leave a comment

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/experts-assess-trump-s-7-point-healthcare-plan?cfcache=true

Troubled health start-up Theranos faces Washington reckoning

Posted on February 13, 2016 by henrykotula • Posted in Uncategorized • Tagged CMS, FDA, Health Care Innovation, Lab Testing, Theranos • Leave a comment

http://www.politico.com/story/2016/02/wunderkind-theranoss-future-is-on-the-line-219162

Elizabeth Holmes is pictured. | Getty

FDA Preps Cracksdown on Stem Cell Clinics Peddling Unproven Treatments

Posted on February 8, 2016 by henrykotula • Posted in Uncategorized • Tagged FDA, Physician, Public Health, Stem Cell Clinics, Unproven Treatments • Leave a comment

FDA moves to crack down on unproven stem cell therapies

Infections From Duodenoscopes Higher Than Previously Estimated

Posted on January 17, 2016 by henrykotula • Posted in Uncategorized • Tagged CRE Infections, Duodenoscope Infections, Endoscopy, FDA, Patient Safety, Quality Care, Superbug Infections • Leave a comment

http://www.californiahealthline.org/articles/2016/1/15/infections-from-duodenoscopes-higher-than-previously-estimated

Implementation Of The Biosimilars Provisions Of The ACA — Where Are We Now?

Posted on December 15, 2015 by henrykotula • Posted in Uncategorized • Tagged ACA, Biosimilars, CMS, FDA, Health Policy, Medicare • Leave a comment

http://healthaffairs.org/blog/2015/12/14/implementation-of-the-biosimilars-provisions-of-the-aca-where-are-we-now/

Blog_MedicalResearch

The 21st Century Cures Act: five things to know

Posted on November 23, 2015 by henrykotula • Posted in Uncategorized • Tagged EHR, FDA, Health Policy, Med Device, NIH, Pharmaceutical, Strategic Oil Reserve • Leave a comment

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/21st-century-cures-act-five-things-know

Endoscope Maker Warned Europe Two Years Before Calif. Outbreaks

Posted on April 21, 2015 by henrykotula • Posted in Uncategorized • Tagged CRE, FDA, Healthcare, Med Device, Superbug • Leave a comment

http://www.californiahealthline.org/articles/2015/4/21/endoscope-maker-warned-europe-two-years-before-calif-outbreaks

	Duncan S. MacLean MD on Biden targets drug costs in St…
	Duncan S. MacLean MD on U.S. healthcare: A conglomerat…
	7 healthcare takeawa… on 7 healthcare takeaways from Se…
	Annette on Cartoon – Fire Fauc…
	sreenadha vattam on Cartoon – US Healthcare…

HENRY KOTULA

A Healthcare Leadership Blog

Tag Archives: FDA

Three drug trends impacting specialty pharmacy

Prescription drug spending surges amid market forces

Kickbacks, Bribes, and the Horrifying Truth Behind California’s Largest Medical Fraud Scandal

Experts assess Trump’s 7-point healthcare plan

Troubled health start-up Theranos faces Washington reckoning

FDA Preps Cracksdown on Stem Cell Clinics Peddling Unproven Treatments

Infections From Duodenoscopes Higher Than Previously Estimated

Implementation Of The Biosimilars Provisions Of The ACA — Where Are We Now?

The 21st Century Cures Act: five things to know

Endoscope Maker Warned Europe Two Years Before Calif. Outbreaks

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: